Mohammed Al-Jumayli, MD

Cancer Focus:
Adrenal Carcinoma, Colorectal Cancer, Esophageal Cancer, Gallbladder Cancer, Gastrointestinal Carcinoid Tumor, Inflammatory Breast Cancer, Kidney (Renal Cell) Cancer, Liver Cancer, Lung Cancer, Neuroendocrine Tumor, Pancreatic Cancer, Prostate Cancer, Small Intestine Cancer, Stomach (Gastric) Cancer

Dr. Al-Jumayli is certified in Hematology, Medical Oncology, and Geriatric Medicine. He received his medical degree from Al-Mustansiriyah University College of Medicine, Iraq. He completed an Internal Medicine Residency at Capital Health Regional Medical Center in New Jersey, followed by a Geriatric Fellowship at Baylor College of Medicine, Texas. He completed a Hematology-Oncology Fellowship at the University of Kansas. Dr. Al-Jumayli’s clinical focus is on the treatment of cancer in senior adults, particularly gastrointestinal Oncolgoy (GI) cancer with providing a personalized cancer care based on patients’ functional status, general health, values, and goals. His research focuses on better understanding patients’ ability to tolerate aggressive cancer therapies based on their biologic age and general health through uncovering specific individual characteristics, genetic mutations and biomarkers. 

Clinical Trial 21227
A Randomized Phase II Study of Gemcitabine and Nab-Paclitaxel Compared with 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan in Older Patients with Treatment Naïve Metastatic Pancreatic Cancer (GIANT)
Condition: Gastrointestinal Tumor
Status: Open

Clinical Trial 22153
Feasibility of Exercise Prehabilitation Among Older Patients with Hepatobiliary Cancer Planning for Surgery
Condition: Gastrointestinal Tumor
Status: Open

If you believe you are eligible for one of these trials or studies, please call
813-745-6100 or toll-free 1-800-679-0775.

• Akhtar OS, Cao B, Wang X, Torka P, Al-Jumayli M, Locke FL, Freeman CL. CAR T-Cell Therapy Has Comparable Efficacy to Autologous Transplantation in Older Adults with DLBCL in Partial Response. Blood Adv. 2023 May. Pubmedid: 37236167.
• Nguyen OT, Lee J, Tabriz AA, Hong YR, Al Jumayli M, Reblin M, Turner K. Evaluation of Employment Loss and Financial Hardship Among US Adults With Disabilities During the COVID-19 Pandemic. JAMA Netw Open. 2023 Mar.6(3):e233364. Pubmedid: 36929405. Pmcid: PMC10020877.
• Nguyen OT, Turner K, Lee J, Hong YR, Al-Jumayli M, Alishahi Tabriz A. Clinical trial knowledge among U.S. adults aged 65 years and up: Findings from a 2020 national survey. J Am Geriatr Soc. 2023 Jun.71(6):1917-1922. Pubmedid: 36715227.
• Al-Jumayli M, Kawsar HI, Neupane P. Clinical Outcomes of Different Treatment Modalities in Anaplastic Thyroid Cancer: A Single Center Experience. Am J Ther. 2023 Jan.29(6):e714-e716. Pubmedid: 32889810.
• Al-Jumayli M, Choucair K, Al-Obaidi A, Park R, Bansal A, Baranda J, Sun W, Saeed A. Pre-operative Carboplatin/Paclitaxel Versus 5-Fluorouracil (5-FU)-based Chemoradiotherapy for Older Adults With Esophageal Cancer. Anticancer Res. 2022 Jan.42(1):59-66. Pubmedid: 34969709.
• Extermann M, Chetty IJ, Brown SL, Al-Jumayli M, Movsas B. Predictors of Toxicity Among Older Adults with Cancer. Semin Radiat Oncol. 2022 Apr.32(2):179-185. Pubmedid: 35307121.
• Al-Jumayli M, Brown SL, Chetty IJ, Extermann M, Movsas B. The Biological Process of Aging and the Impact of Ionizing Radiation. Semin Radiat Oncol. 2022 Apr.32(2):172-178. Pubmedid: 35307120.
• Ripp J, Mohyuddin GR, Al-Jumayli M, Huang C. Outcomes in older patients with NSCLC receiving immunotherapy: A single center experience. Geriatr Oncol. 2021 Sep.12(7):1104-1106. Pubmedid: 33619001.
• Park R, Al-Jumayli M, Miller K, Saeed A, Saeed A. Exceptional response to Erlotinib monotherapy in EGFR Exon 19-deleted, KRAS wild-type, Chemo-refractory advanced pancreatic adenocarcinoma. Cancer Treat Res Commun. 2021 Feb.27:100342. Pubmedid: 33611092.
• Kasi A, Al-Jumayli M, Park R, Baranda J, Sun W. Update on the Role of Poly (ADP-Ribose) Polymerase Inhibitors in the DNA Repair-Deficient Pancreatic Cancers: A Narrative Review. J Pancreat Cancer. 2020 Dec.6(1):107-115. Pubmedid: 33376937. Pmcid: PMC7757687.
• Saeed A, Hildebrand H, Park R, Al-Jumayli M, Abbasi S, Melancon T, Saeed A, Al-Rajabi R, Kasi A, Baranda J, Williamson S, Sun W. Immune Checkpoint Inhibitors versus VEGF Targeted Therapy as Second Line Regimen in Advanced Hepatocellular Carcinoma (HCC): A Retrospective Study. J Clin Med. 2020 Aug.9(9). Pubmedid: 32824968. Pmcid: PMC7563439.
• Park R, Eshrat F, Al-Jumayli M, Saeed A, Saeed A. Immuno-Oncotherapeutic Approaches in Advanced Hepatocellular Carcinoma. Vaccines (Basel). 2020 Aug.8(3). Pubmedid: 32784389. Pmcid: PMC7563532.
• Al-Jumayli M, Batool A, Middiniti A, Saeed A, Sun W, Al-Rajabi R, Baranda J, Kumer S, Schmitt T, Chidharla A, Kasi A. Clinical Outcome of Ampullary Carcinoma: Single Cancer Center Experience. J Oncol. 2019 May.2019:3293509. Pubmedid: 31186632. Pmcid: PMC6521487.
• Saeed A, Park R, Al-Jumayli M, Al-Rajabi R, Sun W. Biologics, Immunotherapy, and Future Directions in the Treatment of Advanced Cholangiocarcinoma. Clin Colorectal Cancer. 2019 May.18(2):81-90. Pubmedid: 30905548.
• Park SC, Hsu AT, Su D, Simonson JL, Al-Jumayli M, Liu Y, Liebmann JM, Ritch R. Factors associated with focal lamina cribrosa defects in glaucoma. Invest Ophth Vis Sci. 2013 Dec.54(13):8401-8407. Pubmedid: 24255039.